百利天恒：公司药物Iza-bren被纳入优先审评程序

Core Viewpoint - The company announced that its self-developed, first-in-class EGFR×HER3 dual antibody ADC (Iza-bren) has been included in the priority review list by the National Medical Products Administration (NMPA) in China, marking a significant milestone in its clinical development [1] Group 1 - Iza-bren is the world's first EGFR×HER3 dual antibody ADC to be included in the priority review list [1] - The drug is currently undergoing over 40 clinical trials in China and the United States for various types of tumors [1]